14/10/2025
๐งฌ๐๐๐๐ ๐๐๐๐: ๐๐๐ง๐จ๐ฆ๐ข๐ ๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง ๐๐ญ ๐ญ๐ก๐ ๐๐๐๐ ๐๐ก๐จ๐ฐ๐๐๐ฌ๐
๐๐ซ๐๐๐ข๐ฌ๐ข๐จ๐ง ๐๐ข๐๐ ๐ง๐จ๐ฌ๐ญ๐ข๐๐ฌ was honoured to be invited to the National Innovation and Commercialisation Expo (NICE) 2025, an innovation platform connecting researchers, startups, corporates, investors, policymakers, and global leaders.
Organised by the ๐๐ข๐ง๐ข๐ฌ๐ญ๐ซ๐ฒ ๐จ๐ ๐๐๐ข๐๐ง๐๐, ๐๐๐๐ก๐ง๐จ๐ฅ๐จ๐ ๐ฒ, ๐๐ง๐ ๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง (MOSTI) and implemented by MRANTI, the event served as a catalyst for Malaysiaโs innovation and biotechnology ecosystem.
๐ต I-Nation sessions explored themes such as AI, health innovation, and policy dialogues, including BioXceed 2025, which focused on bio-commercialisation, accelerators, and bio-based enterprises.
๐ข Discussions emphasised commercialisation and funding, translating research into scalable ventures with sustainable business models.
๐ Panel topics covered global scaling, healthcare system resilience, and challenges faced by bio-based industries.
We extend our appreciation to the Bioeconomy Corporation for the opportunity to showcase ๐๐๐๐๐๐๐ ๐๐ก๐๐ซ๐ฆ๐๐๐จ๐ ๐๐ง๐จ๐ฆ๐ข๐๐ฌ at the NBIO Showcase, a biotechnology and bio-based industry summit highlighting genomic-driven healthcare solutions. Our clinically validated pharmacogenomic test empowers personalised prescribing decisions through actionable genomic insights.
It remains vital for Precision Diagnostics to foster meaningful collaborations and champion the next frontier in precision healthcare. Our participation reflects a strong alignment with the goals of Malaysiaโs National Biotechnology Policy 2.0, which aims to integrate precise, data-driven treatment strategies into real-world clinical practice and deliver measurable benefits to society.
As we move forward, our focus remains on translating genomic innovation into real clinical impact, ๐๐ฆ๐ฉ๐จ๐ฐ๐๐ซ๐ข๐ง๐ ๐๐๐ญ๐ญ๐๐ซ ๐ก๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐จ๐ซ ๐๐ฏ๐๐ซ๐ฒ ๐๐๐ฅ๐๐ฒ๐ฌ๐ข๐๐ง.